What are the latest developments in TAVI for aortic regurgitation? - EuroPCR 2026

In this #europcr 2026 conversation, Andreas Baumbach speaks with Raj Makkar about one of the most rapidly evolving areas in structural heart interventions: TAVI for aortic regurgitation. While TAVI has become an established treatment for aortic stenosis, managing patients with pure native aortic regurgitation remains more challenging. In recent years, dedicated transcatheter devices have been developed and evaluated, with encouraging results in patients who are at high surgical risk or unsuitable for surgery. The discussion focuses on the ALIGN-AR study, which assessed a dedicated TAVI device in patients with symptomatic, moderate-to-severe or severe aortic regurgitation who were not appropriate candidates for surgery. Andreas Baumbach and Raj Makkar review the study design, patient population, and key outcomes, and discuss how these findings may influence clinical practice. They also explore the current guideline recommendations and the future role of transcatheter therapies in the management of aortic regurgitation. Watch this insightful discussion to learn about the latest evidence and emerging treatment options for this challenging patient population. More videos on PCRonline: https://www.pcronline.com/Cases-resou... #tavi, #aorticregurgitation, #aorticstenosis, #transcatheter, #surgery, #guidelines